Karyopharm Therapeutics (KPTI) Return on Capital Employed (2013 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Return on Capital Employed came in at 883.74% in Q4 2025, down 74269.0% YoY from N/an in Q4 2024, and down 13.7% on a QoQ basis from 777.28% in Q3 2025.
Karyopharm Therapeutics (KPTI) Return on Capital Employed (2013 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 13 years of Return on Capital Employed data on file, last reported at 883.74% in Q4 2025.
- Quarterly Return on Capital Employed fell 74269.0% year-over-year to 883.74% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 883.74% (down 74269.0% YoY) and the FY2025 annual result came in at 204.49%, down 9607.0% from the prior year.
- Return on Capital Employed eased to 883.74% in Q4 2025, from 777.28% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 33.7% in Q3 2022 to a low of 883.74% in Q4 2025.
- A 5-year average of 181.95% and a median of 79.81% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed surged 5678 bps — and 2025, when it slumped 74269 bps.
- Tracing KPTI's Return on Capital Employed over 5 years: stood at 47.71% in 2021, then sank by 30 bps to 62.15% in 2022, then decreased by 12 bps to 69.75% in 2023, then tumbled by 102 bps to 141.05% in 2024, then sank by 527 bps to 883.74% in 2025.
- The last three Return on Capital Employed figures came in at 883.74% (Q4 2025), 777.28% (Q3 2025), and 674.55% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | 328.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 328.23% |
| Dec 31, 2025 | -883.74% |
| Sep 30, 2025 | -777.28% |
| Jun 30, 2025 | -674.55% |
| Mar 31, 2025 | -213.56% |
| Dec 31, 2024 | -141.05% |
| Sep 30, 2024 | -89.83% |
| Jun 30, 2024 | -86.38% |
| Mar 31, 2024 | -84.27% |
| Dec 31, 2023 | -69.75% |
| Sep 30, 2023 | -56.62% |
| Jun 30, 2023 | -49.50% |
| Mar 31, 2023 | -49.39% |
| Dec 31, 2022 | -62.15% |
| Sep 30, 2022 | -33.70% |
| Jun 30, 2022 | -34.95% |
| Mar 31, 2022 | -34.49% |
| Dec 31, 2021 | -47.71% |
| Sep 30, 2021 | -90.49% |
| Jun 30, 2021 | -83.37% |